Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dolby Laboratories, Inc. (NYSE: DLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports, quarterly updates, proxy materials, and current reports on material events. As a Delaware corporation with Class A common stock listed on the New York Stock Exchange, Dolby files documents such as Form 10-K, Form 10-Q, Form 8-K, and the Definitive Proxy Statement (DEF 14A) with the U.S. Securities and Exchange Commission.
Dolby’s filings offer detailed insight into its licensing-focused business model, which centers on technologies like Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and related audio and imaging intellectual property. In its proxy statement and other filings, the company discusses its single reportable segment, the importance of royalty-based revenue, and the role of cinema hardware and premium cinema technologies in its overall revenue mix.
Through current reports on Form 8-K, Dolby discloses financial results, dividends, and executive compensation plans. These filings cover quarterly and annual revenue, net income, non-GAAP metrics, and capital return actions such as cash dividends on Class A and Class B common stock. They also describe executive bonus plans that tie incentive payouts to non-GAAP operating income, revenue, and other performance metrics.
The Definitive Proxy Statement (DEF 14A) provides information on corporate governance and executive compensation, including proposals for the election of directors, advisory votes on named executive officer compensation, and ratification of the independent registered public accounting firm. It also summarizes non-GAAP financial measures and includes reconciliations to GAAP in appendices.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, highlight key figures and themes, and make it easier to understand Dolby’s financial condition, risk disclosures, and governance practices. Investors can use this page to follow Dolby’s official communications to regulators, monitor dividend and capital allocation decisions, and review the frameworks used to evaluate and reward the company’s leadership.
Dolby Laboratories shareholder plans new stock sale under Rule 144. A filing reports an intention to sell 34,367 shares of Dolby common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,305,493.01. Dolby had 60,845,846 shares of common stock outstanding.
The 34,367 shares were acquired on 12/09/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the past three months, the Yeaman Family Trust has sold additional Dolby common shares in three transactions of 36,699, 25,000, and 25,000 shares, generating gross proceeds of $2,455,401.64, $1,721,840.00, and $1,791,487.50, respectively.
Dolby Laboratories executive reports stock option exercise and sale. On 12/01/2025, EVP, General Counsel & Secretary Mark Andrew Sherman exercised an employee stock option for 4,500 shares of Dolby Class A common stock at an exercise price of $64.6 per share and acquired these shares.
On the same date, he sold 4,500 shares of Class A common stock at a weighted average price of $67.5635 per share in multiple transactions. Following these transactions, he beneficially owned 62,397 shares of Class A common stock, which include 45,470 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories insider plans Rule 144 share sale. A holder has filed a notice to sell 4,500 shares of common stock of Dolby Laboratories under Rule 144. The proposed sale, through Morgan Stanley Smith Barney LLC on the NYSE, has an aggregate market value of $304,035.75 based on the filing information. The shares were acquired on 12/01/2025 via a stock option exercise from the issuer for cash, and the same number of shares is slated for sale. The filing notes that 60,845,846 shares of the issuer’s common stock were outstanding, providing context for the size of this planned transaction.
Dolby Laboratories, Inc. (DLB) President and CEO Kevin Yeaman, who is also a director, reported multiple transactions in Class A common stock and related stock options. On November 24, 2025, a family trust exercised employee stock options for 25,000 shares at $45.50 and 11,699 shares at $64.60, increasing indirect holdings. That same day, the trust sold 36,699 shares at a weighted average price of $66.9066, with the shares sold in multiple transactions under a Rule 10b5-1 trading plan adopted on February 28, 2025.
On November 26, 2025, Mr. Yeaman gifted 16,348 shares of Class A common stock from the trust to a donor-advised fund for charitable purposes. Following the reported transactions, indirect holdings include 98,377 shares in the family trust and additional indirect ownership through restricted stock units and shares held by a son.
Dolby Laboratories, Inc. (DLB) reported an insider stock sale by a director. On 11/25/2025, a director sold 3,300 shares of Class A common stock in an open market transaction coded "S" at a price of $67.85 per share. After this sale, the director beneficially owned 9,107 shares of Class A common stock.
This remaining amount includes 3,140 shares underlying restricted stock units that are subject to forfeiture until they vest, meaning the director must meet vesting conditions before fully owning those shares.
Dolby Laboratories (DLB) has a planned sale of restricted common stock under Rule 144. The notice covers the proposed sale of 3,300 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $223,905.00. The issuer has 60,845,846 shares of common stock outstanding.
The seller acquired these shares as restricted stock directly from the issuer in two grants: 2,783 shares on 02/06/2023 and 517 shares on 02/05/2024, both noted as not involving special payment arrangements. The approximate date of sale listed in the notice is 11/25/2025.
Dolby Laboratories, Inc. insider activity: A company officer, identified as SVP of the Advanced Technology Group, reported selling 3,000 shares of Dolby Laboratories Class A common stock on 11/21/2025 at a price of $65.55 per share. After this transaction, the reporting person beneficially owns 67,435 shares of Class A common stock.
The remaining holdings include 47,766 shares underlying restricted stock units that may be forfeited if they do not vest, meaning a substantial portion of the reported ownership is still subject to vesting conditions over time.
Dolby Laboratories (DLB) senior vice president of entertainment reported a sale of Class A common stock. On 11/20/2025, the executive sold 6,164 shares of Dolby Class A common stock at a price of $66.12 per share. After this transaction, the executive beneficially owns 115,338 shares of Class A common stock. This total includes 48,526 shares underlying restricted stock units that may be forfeited if they do not vest, as well as 284 shares and 67 shares acquired through the company’s Employee Stock Purchase Plan on May 15, 2025 and November 17, 2025.
Dolby Laboratories (DLB) has a Form 144 notice indicating a planned sale of 36,699 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,455,401.64. The filing notes that 60,845,846 shares of common stock are outstanding.
The shares to be sold were acquired on 11/24/2025 via a stock option exercise from the issuer, paid in cash, on the same date. Over the past three months, the Yeaman Family Trust sold 25,000 common shares on 10/14/2025 for gross proceeds of $1,721,840.00 and another 25,000 shares on 09/16/2025 for $1,791,487.50. The signatory represents that they are not aware of undisclosed material adverse information about Dolby’s operations.
An insider of DLB has filed a Form 144 indicating an intent to sell up to 3,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of 196,650.00. The shares relate to restricted stock awards acquired from the issuer on 05/16/2023 and 05/16/2024, totaling 2,279 and 721 shares respectively, both noted as not involving special payment terms. The notice lists 60,845,846 shares of the issuer’s common stock outstanding and targets an approximate sale date of 11/21/2025 on the NYSE. Over the prior three months, the same seller disposed of 7,000 shares of common stock on 08/22/2025 for gross proceeds of 524,440.00.